See more : GB Sciences, Inc. (GBLX) Income Statement Analysis – Financial Results
Complete financial analysis of iZafe Group AB (publ) (IZAFE-B.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iZafe Group AB (publ), a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Xenetic Biosciences, Inc. (XBIO) Income Statement Analysis – Financial Results
- Is Yatirim Menkul Degerler Anonim Sirketi (ISMEN.IS) Income Statement Analysis – Financial Results
- Basetrophy Group Holdings Limited (8460.HK) Income Statement Analysis – Financial Results
- Long4life Limited (L4L.JO) Income Statement Analysis – Financial Results
- Cera Sanitaryware Limited (CERA.NS) Income Statement Analysis – Financial Results
iZafe Group AB (publ) (IZAFE-B.ST)
About iZafe Group AB (publ)
iZafe Group AB (publ), a life-science company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated drug dispenser that handles dose bags, facilitates and enables independent medication, and reminds and alerts if the current dose is not taken at the right time. It serves consumers, and public and private-sector care providers in Sweden, the Nordic region, and internationally. The company was formerly known as MediRätt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was incorporated in 2008 and is headquartered in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.82M | 729.00K | 442.00K | 8.90M | 14.33M | 7.57M | 155.00K | 0.00 | 0.00 | 0.00 | 5.70K | 39.10K | 26.42K | 3.75K |
| Cost of Revenue | 1.53M | 606.00K | 1.58M | 1.26M | 36.35M | 18.30M | 4.89M | 1.46M | 2.39M | 0.00 | 1.23M | 1.37M | 0.00 | 0.00 |
| Gross Profit | 293.00K | 123.00K | -1.14M | 7.65M | -22.03M | -10.73M | -4.74M | -1.46M | -2.39M | 0.00 | -1.22M | -1.34M | 26.42K | 3.75K |
| Gross Profit Ratio | 16.08% | 16.87% | -257.47% | 85.86% | -153.73% | -141.75% | -3,056.77% | 0.00% | 0.00% | 0.00% | -21,405.93% | -3,414.36% | 100.00% | 100.00% |
| Research & Development | 3.13M | 2.90M | 3.92M | 3.92M | 3.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 19.17M | 17.73M | 17.72M | 11.02M | 3.36M | 4.96M | 535.06K | 1.11M | 1.23M | 1.40M | 2.61M | 3.39M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.80M | 18.90M | 19.17M | 17.73M | 17.72M | 11.02M | 3.36M | 4.96M | 535.06K | 1.11M | 1.23M | 1.40M | 2.61M | 3.39M |
| Other Expenses | 0.00 | 23.63M | 12.96M | 16.01M | 18.63M | 3.00K | 500.00K | 1.51M | 2.39M | 2.40M | 7.35M | 1.63M | 2.34M | 2.51M |
| Operating Expenses | 35.93M | 23.63M | 32.14M | 33.74M | 36.35M | 18.31M | 4.89M | 6.47M | 2.93M | 3.51M | 8.57M | 3.03M | 4.95M | 5.90M |
| Cost & Expenses | 37.46M | 24.24M | 33.72M | 35.00M | 36.35M | 18.31M | 4.89M | 6.47M | 2.93M | 3.51M | 8.57M | 3.03M | 4.95M | 5.90M |
| Interest Income | 159.00K | 0.00 | 0.00 | 1.00K | 3.00K | 0.00 | 0.00 | 158.00 | 18.00 | 23.00 | 28.00 | 120.00 | 79.00 | 0.00 |
| Interest Expense | 240.00K | 182.00K | 3.00M | 731.00K | 614.00K | 391.00K | 31.00K | 106.97K | 107.21K | 98.09K | 90.81K | 40.69K | 22.18K | 8.57K |
| Depreciation & Amortization | 19.86M | 1.47M | 923.00K | 1.44M | 1.83M | 570.00K | 418.00K | 1.46M | 2.39M | 2.39M | 6.90M | 1.21M | 1.63M | 1.63M |
| EBITDA | -15.62M | -21.94M | -32.35M | -10.67M | -20.76M | -10.17M | -3.82M | -5.06M | -535.64K | -1.12M | -1.67M | -1.78M | -3.28M | -4.26M |
| EBITDA Ratio | -857.14% | -2,611.66% | -6,431.22% | -232.87% | -113.53% | -134.32% | -2,464.52% | 0.00% | 0.00% | 0.00% | -29,315.78% | -4,554.18% | -12,433.70% | -113,710.32% |
| Operating Income | -35.64M | -23.40M | -33.27M | -26.09M | -22.57M | -10.74M | -4.24M | -6.47M | -2.93M | -3.51M | -8.57M | -2.99M | -4.92M | -5.90M |
| Operating Income Ratio | -1,955.82% | -3,210.43% | -7,527.83% | -293.06% | -157.49% | -141.84% | -2,734.19% | 0.00% | 0.00% | 0.00% | -150,337.75% | -7,638.94% | -18,620.98% | -157,298.05% |
| Total Other Income/Expenses | -81.00K | -182.00K | -3.00M | -730.00K | -639.00K | -391.00K | -31.00K | -106.81K | -107.19K | -98.07K | -90.78K | -40.57K | -22.10K | -8.57K |
| Income Before Tax | -35.72M | -23.59M | -36.28M | -12.84M | -23.20M | -11.13M | -4.27M | -6.58M | -3.03M | -3.61M | -8.66M | -3.03M | -4.94M | -5.91M |
| Income Before Tax Ratio | -1,960.26% | -3,235.39% | -8,207.01% | -144.23% | -161.95% | -147.01% | -2,754.19% | 0.00% | 0.00% | 0.00% | -151,930.96% | -7,742.69% | -18,704.64% | -157,526.53% |
| Income Tax Expense | -3.54M | -60.00K | 3.00M | -88.00K | -88.00K | 182.00K | 500.00K | -219.07K | -438.14K | -438.14K | -1.43M | -109.54K | 79.00 | 0.00 |
| Net Income | -32.17M | -23.53M | -39.28M | -12.75M | -23.12M | -11.31M | -4.27M | -6.36M | -2.60M | -3.17M | -7.23M | -2.92M | -4.94M | -5.91M |
| Net Income Ratio | -1,765.92% | -3,227.16% | -8,886.20% | -143.24% | -161.33% | -149.41% | -2,754.19% | 0.00% | 0.00% | 0.00% | -126,867.08% | -7,462.56% | -18,704.64% | -157,526.53% |
| EPS | -0.14 | -0.29 | -0.85 | -0.37 | -1.08 | -0.53 | -0.35 | -0.55 | -0.28 | -0.38 | -0.88 | -0.36 | -0.74 | -1.06 |
| EPS Diluted | -0.14 | -0.29 | -0.85 | -0.37 | -1.08 | -0.53 | -0.35 | -0.55 | -0.28 | -0.38 | -0.88 | -0.36 | -0.74 | -1.06 |
| Weighted Avg Shares Out | 231.76M | 79.95M | 46.25M | 34.87M | 21.45M | 21.45M | 12.22M | 11.52M | 9.22M | 8.25M | 8.23M | 8.00M | 6.66M | 5.58M |
| Weighted Avg Shares Out (Dil) | 231.76M | 79.95M | 46.25M | 34.87M | 21.45M | 21.45M | 12.22M | 11.52M | 9.35M | 8.25M | 8.23M | 8.00M | 6.66M | 5.58M |
Source: https://incomestatements.info
Category: Stock Reports